JP2010518128A5 - - Google Patents

Download PDF

Info

Publication number
JP2010518128A5
JP2010518128A5 JP2009549348A JP2009549348A JP2010518128A5 JP 2010518128 A5 JP2010518128 A5 JP 2010518128A5 JP 2009549348 A JP2009549348 A JP 2009549348A JP 2009549348 A JP2009549348 A JP 2009549348A JP 2010518128 A5 JP2010518128 A5 JP 2010518128A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
independently
optionally substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009549348A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010518128A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2008/000293 external-priority patent/WO2008098368A1/en
Publication of JP2010518128A publication Critical patent/JP2010518128A/ja
Publication of JP2010518128A5 publication Critical patent/JP2010518128A5/ja
Pending legal-status Critical Current

Links

JP2009549348A 2007-02-16 2008-02-15 C型肝炎ns3プロテアーゼのインヒビター Pending JP2010518128A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89030407P 2007-02-16 2007-02-16
PCT/CA2008/000293 WO2008098368A1 (en) 2007-02-16 2008-02-15 Inhibitors of hepatitis c ns3 protease

Publications (2)

Publication Number Publication Date
JP2010518128A JP2010518128A (ja) 2010-05-27
JP2010518128A5 true JP2010518128A5 (enExample) 2011-04-07

Family

ID=39689592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009549348A Pending JP2010518128A (ja) 2007-02-16 2008-02-15 C型肝炎ns3プロテアーゼのインヒビター

Country Status (5)

Country Link
US (1) US20100087382A1 (enExample)
EP (1) EP2125870A4 (enExample)
JP (1) JP2010518128A (enExample)
CA (1) CA2676297A1 (enExample)
WO (1) WO2008098368A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
KR20100024920A (ko) * 2007-05-03 2010-03-08 인터뮨, 인크. C형 간염 바이러스 복제의 신규 마크로사이클릭 저해제
MX2009012093A (es) * 2007-05-10 2010-01-25 Intermune Inc Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c.
KR20110005869A (ko) * 2008-04-15 2011-01-19 인터뮨, 인크. C형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
CN102216321A (zh) * 2008-10-15 2011-10-12 因特蒙公司 治疗性抗病毒肽
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9139569B2 (en) 2009-05-12 2015-09-22 Merck Sharp & Dohme Corp. Fused tricyclic aryl compounds useful for the treatment of viral diseases
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8772505B2 (en) 2009-05-29 2014-07-08 Merck Sharp & Dohme Corp. Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis C
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
WO2011038293A1 (en) * 2009-09-28 2011-03-31 Intermune, Inc. Cyclic peptide inhibitors of hepatitis c virus replication
AU2010324871A1 (en) * 2009-11-25 2012-06-14 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
EP2545060B1 (en) * 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
ES2645725T3 (es) 2010-06-11 2017-12-07 Rhodes Technologies Procesos catalizados por metales de transición para la preparación de compuestos de N-alilo y uso de los mismos
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
WO2012092411A2 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SI2909205T1 (sl) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2016148674A1 (en) 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates for treating diseases
CN115806518A (zh) * 2022-12-29 2023-03-17 南京安伦化工科技有限公司 一种N-Boc-4-氧代-脯氨酸甲酯的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006000085A1 (en) * 2004-06-28 2006-01-05 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
US7592336B2 (en) * 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) * 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Similar Documents

Publication Publication Date Title
JP2012526728A5 (enExample)
JP2013508279A5 (enExample)
JP2013523765A5 (enExample)
JP2011523952A5 (enExample)
JP2017523169A5 (enExample)
JP2009504772A5 (enExample)
JP2015500843A5 (enExample)
JP2013537905A5 (enExample)
JP2016006118A5 (enExample)
JP2012524055A5 (enExample)
JP2010535785A5 (enExample)
JP2011520815A5 (enExample)
JP2013532652A5 (enExample)
JP2018135343A5 (enExample)
JP2012092103A5 (enExample)
JP2015517555A5 (enExample)
JP2016518437A5 (enExample)
JP2017510610A5 (enExample)
JP2013503846A5 (enExample)
JP2013545818A5 (enExample)
JP2014513954A5 (enExample)
JP2013538230A5 (enExample)
JP2013537203A5 (enExample)
JP2013545817A5 (enExample)
JP2015522036A5 (enExample)